ICD-10 Logo
ICDxICD-10 Medical Coding
ICD-10 Logo
ICDxICD-10 Medical Coding
ICD 10 CodesDiagnoses
ICD 10 CodesDiagnoses
ICD-10 Logo
ICDxICD-10 Medical Coding

Comprehensive ICD-10-CM code reference with AI-powered search capabilities.

© 2025 ICD Code Compass. All rights reserved.

Browse

  • All Chapters
  • All Categories
  • Diagnoses

Tools

  • AI Code Search
ICD-10-CM codes are maintained by the CDC and CMS. This tool is for reference purposes only.
v1.0.0
ICD-10 Guide
ICD-10 CodesD02.22

D02.22

Billable

Carcinoma in situ of left bronchus and lung

BILLABLE STATUSYes
IMPLEMENTATION DATEOctober 1, 2015
LAST UPDATED09/05/2025

Code Description

ICD-10 D02.22 is a billable code used to indicate a diagnosis of carcinoma in situ of left bronchus and lung.

Key Diagnostic Point:

Carcinoma in situ (CIS) of the left bronchus and lung refers to a localized form of cancer where abnormal cells are present in the lining of the bronchus and lung but have not invaded deeper tissues or metastasized. This condition is characterized by the presence of atypical cells that have the potential to develop into invasive cancer if left untreated. The diagnosis is typically made through imaging studies such as CT scans and confirmed via bronchoscopy and biopsy. Patients may present with symptoms such as cough, hemoptysis, or wheezing, although many cases are asymptomatic. Surveillance protocols often include regular imaging and pulmonary function tests to monitor for progression. The risk of progression to invasive carcinoma varies based on factors such as the size of the lesion, histological subtype, and patient risk factors including smoking history and exposure to carcinogens. Early detection and intervention are crucial to prevent the development of invasive lung cancer.

Code Complexity Analysis

Complexity Rating: Medium

Medium Complexity

Complexity Factors

  • Differentiating between in situ and invasive carcinoma
  • Need for precise documentation of location and extent of disease
  • Variability in clinical presentation and symptoms
  • Potential for concurrent respiratory conditions

Audit Risk Factors

  • Inadequate documentation of biopsy results
  • Failure to specify the exact location of the carcinoma
  • Lack of follow-up documentation for surveillance
  • Misclassification of in situ versus invasive carcinoma

Specialty Focus

Medical Specialties

Oncology

Documentation Requirements

Detailed pathology reports, imaging studies, and treatment plans.

Common Clinical Scenarios

Diagnosis of carcinoma in situ during routine screenings, management of precancerous lesions.

Billing Considerations

Ensure clear documentation of the histological type and any treatment recommendations.

Pulmonology

Documentation Requirements

Pulmonary function tests, imaging results, and clinical notes on respiratory symptoms.

Common Clinical Scenarios

Evaluation of patients with chronic cough or hemoptysis, follow-up after diagnosis.

Billing Considerations

Document any comorbid respiratory conditions that may affect treatment decisions.

Coding Guidelines

Inclusion Criteria

Use D02.22 When
  • According to ICD
  • CM guidelines, carcinoma in situ codes should be used when there is definitive diagnosis through biopsy
  • It is essential to document the specific site and ensure that the condition is not classified as invasive

Exclusion Criteria

Do NOT use D02.22 When
  • Exclusion criteria include any evidence of metastasis or invasion

Related ICD-10 Codes

Related CPT Codes

31625CPT Code

Bronchoscopy, rigid or flexible

Clinical Scenario

Used for diagnosis and biopsy of suspected carcinoma in situ.

Documentation Requirements

Document indication for procedure, findings, and biopsy results.

Specialty Considerations

Pulmonologists should ensure clear documentation of the procedure and any complications.

ICD-10 Impact

Diagnostic & Documentation Impact

Enhanced Specificity

ICD-10 Improvements

The transition to ICD-10 has allowed for more specific coding of carcinoma in situ, improving the accuracy of cancer registries and treatment planning. This specificity aids in tracking patient outcomes and tailoring surveillance protocols.

ICD-9 vs ICD-10

The transition to ICD-10 has allowed for more specific coding of carcinoma in situ, improving the accuracy of cancer registries and treatment planning. This specificity aids in tracking patient outcomes and tailoring surveillance protocols.

Reimbursement & Billing Impact

reimbursement.

Resources

Clinical References

  • •
    ICD-10-CM Official Guidelines for Coding and Reporting

Coding & Billing References

  • •
    ICD-10-CM Official Guidelines for Coding and Reporting

Frequently Asked Questions

What is the difference between carcinoma in situ and invasive carcinoma?

Carcinoma in situ refers to cancer cells that are localized and have not invaded surrounding tissues, while invasive carcinoma has spread beyond the original site into nearby tissues.